Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H. Res. 1331 Introduced in House (IH)]

<DOC>

119th CONGRESS 2d Session H. RES. 1331

Expressing support for the designation of June 1, 2026, through June 7, 2026, as ``Hidradenitis Suppurativa Awareness Week''.

_______________________________________________________________________

IN THE HOUSE OF REPRESENTATIVES

June 2, 2026

Mrs. Dingell (for herself and Mr. Joyce of Pennsylvania) submitted the following resolution; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

RESOLUTION

Expressing support for the designation of June 1, 2026, through June 7, 2026, as ``Hidradenitis Suppurativa Awareness Week''.

Whereas Hidradenitis Suppurativa (in this resolution referred to as ``HS'') is a chronic, inflammatory skin disease that affects approximately 3,300,000 people in the United States; Whereas HS causes painful, boil-like nodules and abscesses anywhere on the body, and can progress to form tunnels under the skin and cause extensive scarring; Whereas individuals with HS frequently suffer from 5 primary domains of physical and emotional suffering, pain, drainage, odor, itching, and profound psychological distress; Whereas HS is associated with one of the highest completed suicide rates among dermatological diseases, second only to melanoma; Whereas 75 percent of individuals with HS are misdiagnosed or not diagnosed until after age 25, missing critical windows for early intervention and care; Whereas delayed diagnosis contributes to worsening disease progression, higher healthcare costs, avoidable emergency room visits, and unnecessary procedures; Whereas individuals are often diagnosed with HS in the prime of their lives, affecting their ability to work, maintain relationships, and participate fully in society; Whereas there are currently only 3 biologic therapies approved by the Food and Drug Administration for the treatment of HS; Whereas additional research is urgently needed to develop new treatments, understand the pathogenesis of the disease, identify biomarkers of HS, and improve outcomes for HS patients; Whereas Federal policy can play a critical role in improving access to biologic therapies, wound care, and comprehensive care for HS patients; and Whereas designating the first week of June as ``Hidradenitis Suppurativa Awareness Week'' would increase public awareness, foster understanding, and catalyze progress in diagnosing, treating, and ultimately curing HS: Now, therefore, be it Resolved, That the House of Representatives-- (1) supports the designation of ``Hidradenitis Suppurativa Awareness Week''; and (2) recognizes the importance of-- (A) increasing awareness and education about HS among the public and health professionals; (B) promoting timely and accurate diagnosis of HS through improved screening and culturally competent care; (C) supporting biomedical research to better understand HS pathogenesis, treatment efficacy, and long-term outcomes; (D) accelerating the development of effective treatments and expanding access to existing therapies for HS; and (E) advancing policies that improve access to care and quality of life for people living with HS and their caregivers. <all>